We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Gladstone Scientists Use Stem Cell Technology to Tackle Huntington’s Disease

Gladstone Scientists Use Stem Cell Technology to Tackle Huntington’s Disease

Gladstone Scientists Use Stem Cell Technology to Tackle Huntington’s Disease

Gladstone Scientists Use Stem Cell Technology to Tackle Huntington’s Disease

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gladstone Scientists Use Stem Cell Technology to Tackle Huntington’s Disease"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists at the UCSF-affiliated Gladstone Institutes and an international team of researchers have generated a human model of Huntington’s disease - directly from the skin cells of patients with the disease.
For years, scientists have studied Huntington’s disease primarily in post-mortem brain tissue or laboratory animals modified to mimic the disease.

In Cell Stem Cell, the international team shows how they developed a human model of Huntington’s disease, which causes a diverse range of neurological impairments.

The new model should help scientists better understand the development of Huntington’s - and provide better ways to identify and screen potential therapeutics for this devastating disease.

This new model comes at a time of concentrated federal efforts to accelerate solutions for diseases - including a number of debilitating conditions that touch only small percentages of the population.

Last year, the National Institutes of Health consolidated its efforts to attack rare diseases under the new National Center for Translational Sciences.

Huntington’s is such a rare disease, although it is the most common inherited neurodegenerative disorder. It afflicts approximately 30,000 people in the United States - with another 75,000 people carrying the gene that will eventually lead to it.

Caused by a mutation in the gene for a protein called huntingtin, the disease damages brain cells so that people with Huntington's progressively lose their ability to walk, talk, think and reason.

“An advantage of this human model is that we now have the ability to identify changes in brain cells over time - during the degeneration process and at specific stages of brain-cell development,” said Gladstone Senior Investigator Steve Finkbeiner, MD, PhD.

Finkbeiner continued, “We hope this model will help us more readily uncover relevant factors that contribute to Huntington’s disease and especially to find successful therapeutic approaches.”

In this research, Finkbeiner and others took advantage of advanced “reprogramming” techniques pioneered by Gladstone Senior Investigator Shinya Yamanaka, MD, PhD.

They reprogrammed skin cells from Huntington’s disease patients into stem cells known as induced pluripotent stem cells, or iPS cells-which can become virtually any cell type in the body.

The researchers then instructed the iPS cells to develop into neurons, a key type of brain cell. Importantly, each cell line contained a complete set of the genes from each Huntington’s disease patient.

Because each patient has a different pattern of disease onset and duration, this model may replicate Huntington’s more faithfully than animal models do. The model is likely to prove more useful in understanding the disease’s progression.

“The iPS cells will provide insights into Huntington’s disease, helping us to develop new therapies and test drug candidates,” said Finkbeiner, who is also a professor of neurology and physiology at UCSF.

Finkbeiner continued, “We hope that drugs developed with this new human model will have greater success in clinical trials. The track record of animal models for predicting therapies that will work in people has been poor, making drug discovery for neurodegenerative diseases very costly - and therefore less attractive to drug companies. We hope to change that.”